Description:
Letrasan is a medication containing the active substance letrozole. It is primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women. Letrozole belongs to a class of drugs known as aromatase inhibitors, which work by reducing the production of estrogen in the body. By lowering estrogen levels, Letrasan helps slow down or stop the growth of hormone-sensitive tumors.

Indications:
Letrasan is indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is often used as adjuvant therapy following surgery or other treatments to reduce the risk of cancer recurrence. Letrasan may also be used in combination with other medications or therapies as part of a comprehensive treatment regimen for breast cancer.

Mechanism of Action:
Letrozole works by inhibiting the enzyme aromatase, which is responsible for converting androgens (male hormones) into estrogen (female hormone) in peripheral tissues. By blocking aromatase activity, Letrasan reduces the production of estrogen, thereby depriving hormone-sensitive breast cancer cells of the estrogen they need to grow and proliferate.

Dosage and Administration:
The recommended dosage of Letrasan is typically 2.5 mg once daily, administered orally with or without food. The duration of treatment may vary depending on factors such as the stage and aggressiveness of the cancer, as well as the patient’s response to therapy. It is essential to follow the healthcare provider’s instructions regarding dosage and duration of treatment.

Side Effects:
Common side effects of Letrasan may include hot flashes, fatigue, joint pain, headache, nausea, and bone thinning (osteoporosis). Some patients may experience more severe side effects, such as elevated liver enzymes, mood changes, or allergic reactions. It is crucial to report any adverse effects to the healthcare provider promptly.

Precautions:
Letrozole should be used with caution in patients with liver or kidney impairment, osteoporosis, or a history of cardiovascular disease. It is not recommended for use in premenopausal women or individuals with a known hypersensitivity to letrozole or any of the components in the formulation.

Manufacturer:
Letrasan is manufactured by DEVA, a pharmaceutical company committed to providing high-quality and affordable generic medications. DEVA focuses on producing a wide range of pharmaceutical products to meet the needs of patients worldwide.

Letrasan is an essential medication in the treatment of hormone receptor-positive breast cancer, helping to reduce the risk of cancer recurrence and improve patient outcomes. It should only be used under the supervision of a qualified healthcare professional and in accordance with applicable laws and regulations. The information provided here is for educational purposes only and should not be construed as medical advice.